TENIDAP

被引：21

作者：

MADHOK, R

机构：

[1] Centre for Rheumatic Diseases, Glasgow Royal Infirmary University NHS Trust, Glasgow, E4 OSF

来源：

LANCET | 1995年 / 346卷 / 8973期

关键词：

D O I：

10.1016/S0140-6736(95)91326-2

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：481 / 485

页数：5

共 23 条

[1]

BEEDVELD F, 1994, SCAND J RHEUMAT S100, V23, P31

[2] TENIDAP, IN CONTRAST TO SEVERAL AVAILABLE NONSTEROIDAL ANTIINFLAMMATORY DRUGS, POTENTLY INHIBITS THE RELEASE OF ACTIVATED NEUTROPHIL COLLAGENASE [J].

BLACKBURN, WD ;

LOOSE, LD ;

HECK, LW ;

CHATHAM, WW .

ARTHRITIS AND RHEUMATISM, 1991, 34 (02) :211-216

[3]

BLACKBURN WD, 1992, ARTHRITIS RHEUM, V35, pS97

[4] 2ND LINE (DISEASE-MODIFYING) TREATMENT IN RHEUMATOID-ARTHRITIS - WHICH DRUG FOR WHICH PATIENT [J].

CAPELL, HA ;

PORTER, DR ;

MADHOK, R ;

HUNTER, JA .

ANNALS OF THE RHEUMATIC DISEASES, 1993, 52 (06) :423-428

[5]

CARTY T J, 1988, Arthritis and Rheumatism, V31, pS89

[6] USE OF SHORT-TERM EFFICACY TOXICITY TRADEOFFS TO SELECT 2ND-LINE DRUGS IN RHEUMATOID-ARTHRITIS - A METAANALYSIS OF PUBLISHED CLINICAL-TRIALS [J].

FELSON, DT ;

ANDERSON, JJ ;

MEENAN, RF .

ARTHRITIS AND RHEUMATISM, 1992, 35 (10) :1117-1125

[7] THE EFFICACY AND TOXICITY OF COMBINATION THERAPY IN RHEUMATOID-ARTHRITIS - A METAANALYSIS [J].

FELSON, DT ;

ANDERSON, JJ ;

MEENAN, RF .

ARTHRITIS AND RHEUMATISM, 1994, 37 (10) :1487-1491

[8] THE RELATIVE TOXICITY OF DISEASE-MODIFYING ANTIRHEUMATIC DRUGS [J].

FRIES, JF ;

WILLIAMS, CA ;

RAMEY, D ;

BLOCH, DA .

ARTHRITIS AND RHEUMATISM, 1993, 36 (03) :297-306

[9] MECHANISMS OF DISEASE - RHEUMATOID-ARTHRITIS - PATHOPHYSIOLOGY AND IMPLICATIONS FOR THERAPY [J].

HARRIS, ED .

NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (18) :1277-1289

[10]

KIRBY DS, 1993, ARTHRITIS RHEUM S9, V30, P112

← 1 2 3 →